Arvinas (ARVN)
(Delayed Data from NSDQ)
$26.16 USD
+0.12 (0.46%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $26.15 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.16 USD
+0.12 (0.46%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $26.15 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Zacks News
Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?
by Zacks Equity Research
Novartis' (NVS) efforts to ward off generic competition for its top cardiovascular drug, Entresto, face a setback.
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas (ARVN) delivered earnings and revenue surprises of 31.94% and 20.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View
by Zacks Equity Research
Novartis' (NVS) second-quarter earnings and sales beat estimates. Based on strong momentum, the company raises its operating income outlook for 2024.
Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Arvinas (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?
by Zacks Equity Research
Cytek Biosciences (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Acadia (ACHC), Geisinger JV Begin Construction of New Hospital
by Zacks Equity Research
The new hospital from Acadia (ACHC) and Geisinger JV is scheduled to open in spring 2025.
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arvinas (ARVN) delivered earnings and revenue surprises of 34.46% and 18.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Arvinas (ARVN)
by Zacks Equity Research
Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Arvinas (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
by Zacks Equity Research
Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
by Zacks Equity Research
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
Is Arvinas (ARVN) Stock a Solid Choice Right Now?
by Kaibalya Pravo Dey
Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is a Surprise Coming for Arvinas (ARVN) This Earnings Season?
by Zacks Equity Research
Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -90.23% and 210.76%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 30.2% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Arvinas, Inc. (ARVN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Can Tenet's (THC) Q4 Earnings Beat on Rising Patient Admissions?
by Zacks Equity Research
Tenet's (THC) fourth-quarter results are likely to reflect higher Ambulatory Care operating revenues and supply costs.
Wall Street Analysts Think Arvinas, Inc. (ARVN) Could Surge 26.67%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Arvinas, Inc. (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Encompass Health (EHC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Encompass Health's (EHC) fourth-quarter results are likely to reflect pricing increases and growing volumes.
Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Will High Medical Costs Affect Centene's (CNC) Q4 Earnings?
by Zacks Equity Research
Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and overall memberships.
Cigna (CI) to Report Q4 Earnings: Can Rising Expenses Hurt?
by Zacks Equity Research
Cigna's (CI) fourth-quarter results are likely to reflect growth in Evernorth revenues and customer base.